Posted by Michael Wonder on 21 Sep 2020
Lynparza recommended for approval in EU by CHMP as first-line maintenance treatment with bevacizumab for HRD positive advanced ovarian cancer
21 September 2020 - Patients treated with Lynparza and bevacizumab lived without disease progression for a median of 37.2 months vs. 17.7 months for bevacizumab alone.
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union for the first-line maintenance treatment with bevacizumab of patients with homologous recombination deficient positive advanced ovarian cancer.
The CHMP of the EMA based its positive opinion on a biomarker subgroup analysis of the PAOLA-1 Phase 3 trial, which was published in The New England Journal of Medicine.
